目的 探究強化劑量阿托伐他汀對不穩(wěn)定型心絞痛患者介入治療（PCI）術(shù)后心肌炎癥反應(yīng)的影響。方法 選取2012年1月—2014年1月焦作煤業(yè)（集團）有限責任公司中央醫(yī)院接收治療的不穩(wěn)定型心絞痛患者88例，隨機分為治療組（44例）和對照組（44例）。治療組患者PCI術(shù)前口服阿托伐他汀鈣片80 mg/d，術(shù)后口服40 mg/d。對照組患者術(shù)前口服20 mg/d，術(shù)后口服20 mg/d阿托伐他汀鈣片。比較兩組患者術(shù)前、術(shù)后SOCS1 mRNA、蛋白表達、血清干擾素-γ（IFN-γ）、超敏C反應(yīng)蛋白（hs-CRP）、腫瘤壞死因子-α（TNF-α）、白細胞介素-10（IL-10）等炎癥因子的表達。結(jié)果 術(shù)后治療組SOCS1 mRNA、蛋白表達均較治療前顯著升高，治療前后差異有統(tǒng)計學(xué)意義（P<0.05）；且治療后治療組這兩者的表達均高于對照組，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。術(shù)后兩組IFN-γ、hs-CRP、TNF-α、IL-10水平均較術(shù)前有所提高，同組治療前后差異有統(tǒng)計學(xué)意義（P<0.05）；術(shù)后，治療組IFN-γ、hs-CRP、TNF-α顯著低于對照組，而IL-10水平高于對照組，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 強化劑量阿托伐他汀可以通過上調(diào)SOCS1的表達，并調(diào)節(jié)炎癥因子IFN-γ、hs-CRP、TNF-α、IL-10水平從而減輕不穩(wěn)定型心絞痛介入治療術(shù)后的心肌炎癥反應(yīng)。

Objective To investigate the influence of strengthening dosage atorvastatin in the treatment of myocardial inflammation after PCI patients with unstable angina. Methods Collecting 88 cases suffered from unstable angina in Jiaozuo Coal Industry Group Central Hospital from January 2012 January 2014, which were randomly divided into treatment (44 cases) and control (44 cases) group. The patients in the treatment group were po administered with Atorvastatin Tablets, 80 mg/d before PCI, then 40 mg/d after PCI. The patients in the control group were po administered with Atorvastatin Tablets, 20 mg/d before PCI, then 20 mg/d after PCI. Expression of SOCS1 mRNA and protein, inflammatory cytokine such as IFN-γ, hs-CRP, TNF-α, and IL-10 in the two groups were compared. Results After the treatment, the expression of SOCS1 mRNA and protein in the treatment group was increased significantly, and the difference was statistically significant before and after the treatment (P < 0.05). And after the treatment the two indicators of the treatment group were higher than those of control group, and there were differences between the two groups (P < 0.05). After the treatment, the levels of IFN-γ, hs-CRP, TNF-α, IL-10 in the two groups were significantly increased, and the differences were statistically significant before and after the treatment in the same group (P < 0.05). After the treatment, IFN-γ, hs-CRP and TNF-α in the treatment group was significantly lower than those in the control group, while IL-10 was higher than that in the control group, and there were differences between the two groups (P < 0.05). Conclusion Atorvastatin in strengthening dosage can increase the expression of SOCS1 and modulate inflammatory factors such as IFN-γ, hs-CRP, TNF-α, and IL-10 so as to reduce myocardial inflammation of patients with unstable angina after PCI.

首都醫(yī)科大學(xué)基礎(chǔ)臨床合作課題（13JL44）